Why the study?
Endothelial cell glycocalyx shedding from disturbed flow and chemical factors causes vascular dysfunction and atherosclerosis, prompting evaluation of a combined sphingosine-1-phosphate and heparin therapy to restore mechanotransduction function.
Does co-therapy with sphingosine-1-phosphate and heparin restore endothelial glycocalyx and combat pro-atherosclerotic endothelial dysfunction in disturbed flow models?
Population
In vitro flow chamber models and partial carotid ligation mouse models
Comparison
Heparin and albumin-bound S1P therapy vs untreated disturbed flow conditions
Design
Preclinical in vitro and in vivo laboratory study
Authors
Loading...
Should not yet change practice; leaves open human translation of this co-therapy for early atherosclerosis.
Does co-therapy with sphingosine-1-phosphate and heparin restore endothelial glycocalyx and combat pro-atherosclerotic endothelial dysfunction in disturbed flow models?
Co-therapy with S1P and heparin restores the endothelial glycocalyx and improves endothelial function in preclinical models of disturbed blood flow, suggesting a potential therapeutic approach for atherosclerosis.
Mitra et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: